JP2021001196A5 - - Google Patents

Download PDF

Info

Publication number
JP2021001196A5
JP2021001196A5 JP2020155460A JP2020155460A JP2021001196A5 JP 2021001196 A5 JP2021001196 A5 JP 2021001196A5 JP 2020155460 A JP2020155460 A JP 2020155460A JP 2020155460 A JP2020155460 A JP 2020155460A JP 2021001196 A5 JP2021001196 A5 JP 2021001196A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
dosage form
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020155460A
Other languages
English (en)
Japanese (ja)
Other versions
JP6942853B2 (ja
JP2021001196A (ja
Filing date
Publication date
Priority claimed from JP2020049467A external-priority patent/JP6850922B2/ja
Application filed filed Critical
Publication of JP2021001196A publication Critical patent/JP2021001196A/ja
Priority to JP2021047526A priority Critical patent/JP2021098757A/ja
Publication of JP2021001196A5 publication Critical patent/JP2021001196A5/ja
Application granted granted Critical
Publication of JP6942853B2 publication Critical patent/JP6942853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020155460A 2015-05-28 2020-09-16 Jakキナーゼ阻害剤としてのナフチリジン化合物 Active JP6942853B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021047526A JP2021098757A (ja) 2015-05-28 2021-03-22 Jakキナーゼ阻害剤としてのナフチリジン化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562167694P 2015-05-28 2015-05-28
US62/167,694 2015-05-28
US201662312273P 2016-03-23 2016-03-23
US62/312,273 2016-03-23
JP2020049467A JP6850922B2 (ja) 2015-05-28 2020-03-19 Jakキナーゼ阻害剤としてのナフチリジン化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020049467A Division JP6850922B2 (ja) 2015-05-28 2020-03-19 Jakキナーゼ阻害剤としてのナフチリジン化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021047526A Division JP2021098757A (ja) 2015-05-28 2021-03-22 Jakキナーゼ阻害剤としてのナフチリジン化合物

Publications (3)

Publication Number Publication Date
JP2021001196A JP2021001196A (ja) 2021-01-07
JP2021001196A5 true JP2021001196A5 (enExample) 2021-05-06
JP6942853B2 JP6942853B2 (ja) 2021-09-29

Family

ID=56118022

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017561259A Active JP6692836B2 (ja) 2015-05-28 2016-05-26 Jakキナーゼ阻害剤としてのナフチリジン化合物
JP2020049467A Active JP6850922B2 (ja) 2015-05-28 2020-03-19 Jakキナーゼ阻害剤としてのナフチリジン化合物
JP2020155460A Active JP6942853B2 (ja) 2015-05-28 2020-09-16 Jakキナーゼ阻害剤としてのナフチリジン化合物
JP2021047526A Withdrawn JP2021098757A (ja) 2015-05-28 2021-03-22 Jakキナーゼ阻害剤としてのナフチリジン化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017561259A Active JP6692836B2 (ja) 2015-05-28 2016-05-26 Jakキナーゼ阻害剤としてのナフチリジン化合物
JP2020049467A Active JP6850922B2 (ja) 2015-05-28 2020-03-19 Jakキナーゼ阻害剤としてのナフチリジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021047526A Withdrawn JP2021098757A (ja) 2015-05-28 2021-03-22 Jakキナーゼ阻害剤としてのナフチリジン化合物

Country Status (31)

Country Link
US (6) US9725470B2 (enExample)
EP (2) EP3303348B1 (enExample)
JP (4) JP6692836B2 (enExample)
KR (1) KR20180011272A (enExample)
CN (2) CN107667108B (enExample)
AU (2) AU2016267141B2 (enExample)
BR (1) BR112017025542A2 (enExample)
CA (1) CA2983453A1 (enExample)
CL (1) CL2017002994A1 (enExample)
CO (1) CO2017012267A2 (enExample)
CY (1) CY1122279T1 (enExample)
DK (1) DK3303348T3 (enExample)
EA (1) EA032953B1 (enExample)
ES (2) ES2924698T3 (enExample)
HU (1) HUE046130T2 (enExample)
IL (3) IL255358B (enExample)
LT (1) LT3303348T (enExample)
ME (1) ME03610B (enExample)
MX (2) MX383074B (enExample)
PH (1) PH12017502050A1 (enExample)
PL (1) PL3303348T3 (enExample)
PT (1) PT3303348T (enExample)
RS (1) RS59522B1 (enExample)
SA (1) SA517390337B1 (enExample)
SG (1) SG10201910742VA (enExample)
SI (1) SI3303348T1 (enExample)
SM (1) SMT201900587T1 (enExample)
TW (2) TWI746178B (enExample)
UA (1) UA121138C2 (enExample)
WO (1) WO2016191524A1 (enExample)
ZA (1) ZA201707326B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのナフチリジン化合物
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
PT3672965T (pt) 2017-10-27 2022-09-29 Theravance Biopharma R&D Ip Llc Composto de pirimidina como inibidor de jak cinase
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111601804B (zh) * 2018-11-27 2024-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
CN111511738B (zh) * 2018-11-30 2023-01-20 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AR118767A1 (es) * 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
ES2974577T3 (es) 2019-04-24 2024-06-27 Theravance Biopharma R&D Ip Llc Compuestos éster y carbonato de pirimidina como inhibidores de JAK quinasa
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021238908A1 (zh) * 2020-05-25 2021-12-02 上海翰森生物医药科技有限公司 杂芳类衍生物的盐、晶型及其制备方法
CN113717202B (zh) * 2020-05-25 2025-10-17 上海翰森生物医药科技有限公司 杂芳类衍生物的自由碱晶型及其制备方法
TW202228689A (zh) * 2020-10-09 2022-08-01 美商賽若凡斯生物製藥研發智財有限責任公司 泛jak抑制劑的調配物
CN116368134A (zh) * 2020-10-09 2023-06-30 施万生物制药研发Ip有限责任公司 制备泛jak抑制剂的方法和相关中间体化合物
WO2022076714A1 (en) 2020-10-09 2022-04-14 Janssen Biotech, Inc. Solid forms of a pan-jak inhibitor
WO2022076717A1 (en) 2020-10-09 2022-04-14 Janssen Biotech, Inc. Solvate forms of a pan-jak inhibitor
WO2022165529A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
WO2022241188A1 (en) 2021-05-14 2022-11-17 Theravance Biopharma R&D Ip, Llc Enantioselective synthesis of aminotropane compound
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
WO2023102800A1 (en) 2021-12-09 2023-06-15 Theravance Biopharma R&D Ip, Llc Synthesis of 5, 7-dichloro-1, 6-naphthyridine
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
EP4563580A4 (en) 2022-07-27 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Fused cyclic compound, its preparation process and its medicinal application
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
CA2588220A1 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors
US20110269740A1 (en) * 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
EP2324022A1 (de) * 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
JP2012504157A (ja) 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CN105367555B (zh) 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのナフチリジン化合物
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2021001196A5 (enExample)
JP2006516570A5 (enExample)
JP2011037832A5 (enExample)
JP5557989B2 (ja) イバンドロネートを含む経口薬理製剤
JP2015518885A5 (enExample)
JPWO2023027198A5 (enExample)
JP2017525712A5 (enExample)
JP6301934B2 (ja) チカグレロルを含む固形経口医薬製剤
JP2015091822A5 (enExample)
JP2016537347A5 (enExample)
KR20110007602A (ko) 심장혈관계 질병 예방용 캡슐
JP2020510085A5 (enExample)
JP2015521191A5 (enExample)
JP2008516004A5 (enExample)
JP2019526591A5 (enExample)
JP2018503611A5 (enExample)
JP2021113228A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2021512869A5 (enExample)
JP2018118966A5 (enExample)
CN102755336A (zh) 包含格雷类药物和阿司匹林盐的药物组合物
JP2007197357A5 (enExample)
JP2005132803A (ja) 胃内滞留固形剤
JPH0692849A (ja) フラン誘導体を含有する医薬組成物
JP4547888B2 (ja) 胃内浮遊性固形製剤
JP2017002092A5 (enExample)